AstraZeneca Pharma announced on Tuesday that it has received approval from the national drug regulator to market a new cancer treatment drug in India.

The company has been granted approval by the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute Trastuzumab Deruxtecan for an additional indication in the country, according to an official statement.

With this approval, Trastuzumab Deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumours. These patients must have received prior systemic therapy and have no satisfactory alternative treatment options.

This approval marks the first and only antibody-drug conjugate in India with a tumour-agnostic indication, representing a significant advancement in precision oncology, AstraZeneca said.

*Disclaimer:*
This story has been sourced from a third-party syndicated feed/ agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability, and accuracy of the text. Mid-day management and mid-day.com reserve the sole right to alter, delete, or remove (without notice) the content at their absolute discretion for any reason whatsoever.

Help us improve further by providing more detailed feedback and stand a chance to win a 3-month e-paper subscription!
https://www.mid-day.com/news/india-news/article/astrazeneca-gets-nod-to-market-cancer-drug-in-india-23597685